Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jean François Rossignol"'
Autor:
Claudio Fenizia, Salomè Valentina Ibba, Claudia Vanetti, Sergio Strizzi, Jean-François Rossignol, Mara Biasin, Daria Trabattoni, Mario Clerici
Publikováno v:
Infectious Disease Reports, Vol 13, Iss 3, Pp 636-644 (2021)
We previously investigated the role of Nitazoxanide (NTZ), a thiazolide endowed with antiviral and antiparasitic activity, in HIV-1 infection. NTZ treatment in primary isolated PBMCs was able to reduce HIV-1 infection in vitro by inducing the express
Externí odkaz:
https://doaj.org/article/9e90e89fc9c64101be1a1a3fcf0f76cd
Autor:
Jean-François Rossignol, Matthew C. Bardin, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot
Publikováno v:
EClinicalMedicine, Vol 45, Iss , Pp 101310- (2022)
Summary: Background: There is an urgent need for treatments of mild or moderate COVID-19 in an outpatient setting. Methods: A randomized double-blind placebo-controlled clinical trial in 36 centers in the U.S. between August 2020 and February 2021 in
Externí odkaz:
https://doaj.org/article/65c59cde098f42a289d639b20e99d7a9
Publikováno v:
Hepatology Communications, Vol 3, Iss 6, Pp 744-747 (2019)
Chronic infection by the hepatitis B virus (HBV) has remained a major public health problem. To achieve an HBV cure, we will likely need to combine antivirals with different viral targets as well as immunotherapy. Here, we report data from a pilot pr
Externí odkaz:
https://doaj.org/article/8f4fa20270364a48b4f22ebc88cc02a0
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Autor:
Jean-François Rossignol
Publikováno v:
Journal of Infection and Public Health, Vol 9, Iss 3, Pp 227-230 (2016)
Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus
Externí odkaz:
https://doaj.org/article/8d7bc7c7794541b0b08c44aef817d3d7
Autor:
Noureddine Hammad, Céline Ransy, Benoit Pinson, Jeremy Talmasson, Christian Bréchot, Frédéric Bouillaud, Jean-François Rossignol
BackgroundViruses are dependent on cellular energy metabolism for their replication, the drug Nitazoxanide (Alinia) was shown to interfere with both. An effect of Alinia on cellular energy metabolism is the uncoupling of mitochondrial oxidative phosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ecfcc878fb73a903d6b01446144da89
https://doi.org/10.1101/2022.09.16.508272
https://doi.org/10.1101/2022.09.16.508272
Autor:
Lisa Miorin, Chad E. Mire, Shahin Ranjbar, Adam J. Hume, Jessie Huang, Nicholas A. Crossland, Kris M White, Manon Laporte, Thomas Kehrer, Viraga Haridas, Elena Moreno, Aya Nambu, Sonia Jangra, Anastasija Cupic, Marion Dejosez, Kristine A. Abo, Anna E. Tseng, Rhiannon B. Werder, Raveen Rathnasinghe, Tinaye Mutetwa, Irene Ramos, Julio Sainz de Aja, Carolina Garcia de Alba Rivas, Michael Schotsaert, Ronald B. Corley, James V. Falvo, Ana Fernandez-Sesma, Carla Kim, Jean-François Rossignol, Andrew A. Wilson, Thomas Zwaka, Darrell N. Kotton, Elke Mühlberger, Adolfo García-Sastre, Anne E. Goldfeld
Publikováno v:
bioRxiv
A well-tolerated and cost-effective oral drug that blocks SARS-CoV-2 growth and dissemination would be a major advance in the global effort to reduce COVID-19 morbidity and mortality. Here, we show that the oral FDA-approved drug nitazoxanide (NTZ) s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945ea80f17c5b78795ee125d768d7ff6
https://doi.org/10.1101/2022.02.08.479634
https://doi.org/10.1101/2022.02.08.479634
Autor:
Jean-François Rossignol
Publikováno v:
Future Virology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df872a6a6e3bc799eae011b78a6dd85f
http://europepmc.org/articles/PMC8756609
http://europepmc.org/articles/PMC8756609
Autor:
El Hadji, Diawara, Arnaud, François, Andrew V, Stachulski, Romy, Razakandrainibe, Damien, Costa, Loïc, Favennec, Jean-François, Rossignol, Gilles, Gargala
Publikováno v:
Parasitology. 148(8)
Cryptosporidiosis is a gastrointestinal illness with profuse diarrhoea. Although there are no other Food and Drug Administration (FDA)-approved alternatives for the treatment of cryptosporidiosis, nitazoxanide (NTZ) can be qualified as partially effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28cb758ed0599405a3443e24cd4b0d60
https://pubmed.ncbi.nlm.nih.gov/33775260
https://pubmed.ncbi.nlm.nih.gov/33775260
Autor:
Simone La Frazia, M. Gabriella Santoro, Jean–François Rossignol, Giuseppe Belardo, O Cenciarelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1061-1069
The emergence of drug-resistant influenza A virus (IAV) strains represents a serious threat to global human health and underscores the need for novel approaches to anti-influenza chemotherapy. Combination therapy with drugs affecting different IAV ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f679a1b7e648c80dc5373ce70e12a8ec
https://doi.org/10.1128/aac.03947-14
https://doi.org/10.1128/aac.03947-14
Publikováno v:
The Journal of Clinical Pharmacology. 54:987-994
In this randomized, double-blind, placebo controlled study, the safety of therapeutic (675 mg) and supra-therapeutic (2,700 mg) doses of nitazoxanide was evaluated in accordance with the ICH E14 guidelines. Fifty six (56) subjects participated in fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08dc2d505799cb8662718ac21f9cb76a
https://doi.org/10.1002/jcph.300
https://doi.org/10.1002/jcph.300